ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures

ClinicalTrials.gov ID: NCT00152516

Public ClinicalTrials.gov record NCT00152516. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 2:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures.

Study identification

NCT ID
NCT00152516
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Pharma
Industry
Enrollment
255 participants

Conditions and interventions

Interventions

  • levetiracetam (LEV) Drug

Drug

Eligibility (public fields only)

Age range
1 Month to 16 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2004
Primary completion
May 31, 2008
Completion
May 31, 2008
Last update posted
Feb 11, 2013

2004 – 2008

United States locations

U.S. sites
38
U.S. states
24
U.S. cities
38
Facility City State ZIP Site status
Not listed Mobile Alabama
Not listed Phoenix Arizona
Not listed Los Angeles California
Not listed Denver Colorado
Not listed Washington D.C. District of Columbia
Not listed Bradenton Florida
Not listed Loxahatchee Groves Florida
Not listed Orlando Florida
Not listed Pensacola Florida
Not listed Tallahassee Florida
Not listed Tampa Florida
Not listed Atlanta Georgia
Not listed Augusta Georgia
Not listed Chicago Illinois
Not listed New Orleans Louisiana
Not listed Boston Massachusetts
Not listed Saint Paul Minnesota
Not listed Lebanon New Hampshire
Not listed Edison New Jersey
Not listed Voorhees Township New Jersey
Not listed Buffalo New York
Not listed New York New York
Not listed Rochester New York
Not listed Syracuse New York
Not listed Chapel Hill North Carolina
Not listed Cleveland Ohio
Not listed Hershey Pennsylvania
Not listed Philadelphia Pennsylvania
Not listed Charleston South Carolina
Not listed Germantown Tennessee
Not listed Nashville Tennessee
Not listed Fort Worth Texas
Not listed Galveston Texas
Not listed Salt Lake City Utah
Not listed Norfolk Virginia
Not listed Richmond Virginia
Not listed Morgantown West Virginia
Not listed Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00152516, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 11, 2013 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00152516 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →